iScience Volume 27, Issue 2, 16 February 2024, 108887
https://doi.org/10.1016/j.isci.2024.108887
Summary on UB-612 COVID vaccine
- UB-612 is a safe vaccine with immunity mimicking natural infection immunity.
- It targets S1-RBD & conserved T-cell epitopes on both the Spike & non-Spike proteins, producing neutralizing antibody titers & T cell immunity with competitive edges over currently authorized vaccines.
- It has 0% hospital & ICU admissions over 12 months, and only 1.2% of any infection at 6 weeks after the Omicron outbreak.
- Potent memory cytotoxic CD8+ T cell immunity underpins the control of disease severity.
- UB-612 can serve as an effective primer & booster for those at risk of SARS-CoV-2 infection.